Slamon, D <br/><br/>
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.  [electronic resource] 

 -  Seminars in oncology  Feb 2001 
 - 13-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0093-7754 
<br/><br/><label>Standard No.: </label>10.1016/s0093-7754(01)90188-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Cisplatin--administration & dosage<br/>Clinical Trials as Topic<br/>Docetaxel<br/>Drug Synergism<br/>Genes, erbB-2<br/>Heart Failure--chemically induced<br/>Humans<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Proto-Oncogene Mas<br/>Taxoids<br/>Trastuzumab